行情

OASMY

OASMY

Vivesto
EXMKT

实时行情|Nasdaq Last Sale

0.197
0.000
0.00%
已收盘, 16:00 08/11 EDT
开盘
--
昨收
0.197
最高
--
最低
--
成交量
--
成交额
--
52周最高
1.223
52周最低
0.197
市值
3,268.53万
市盈率(TTM)
-6.0367
分时
5日
1月
3月
1年
5年
暂无数据
暂无数据
了解OASMY最新的财务预测,通过OASMY每股收益,每股净资产,每股现金流等数据分析Vivesto近期的经营情况,然后做出明智的投资选择。
EPS
实际EPS
预期EPS
0.000.010.030.04
Q4 2020
Q1 2021
Q2 2021
Q3 2021
    0
Q4 2021
机构持股
总机构数: 4
机构持股: 3.86万
持股比例: 0.02%
总股本: 1.66亿
类型机构数股数
增持
0
0
建仓
1
2,600
减持
2
907
平仓
5
4.57万
  • 业绩
  • 资产分布
  • 分红历史
暂无数据
所属板块
制药
+1.44%
制药与医学研究
+1.45%
高管信息
Chairman/Director
Julian Aleksov
Chief Executive Officer
Mikael Asp
Chief Financial Officer/Executive Vice President
Anders Blom
Chief Accounting Officer
Magdalena Berg
Other
Dzianis Babrou
Other
John Cosby
Other
Nina Heldring
Other
Henrik Ronnberg
Director
Bo Cederstrand
Director
Per Lango
Independent Director
Lars Bergkvist
Independent Director
Alexander Kotsinas
暂无数据
暂无数据
OASMY 简况
Oasmia Pharmaceutical AB is a Sweden-based pharmaceutical company dedicated to improving the lives of patients by enhancing the intravenous delivery of drugs in diseases such as cancer. Product development is based on Oasmia’s drug delivery platform which can be applied to medicines used in many therapeutic areas, to develop water soluble formulations of drugs that usually require chemical solubilizers for dissolution. The Company's approved product that is using this technology is Apealea (paclitaxel micellar). Apealea has market authorization in the European Union and several other territories for the treatment of first relapse in platinum-sensitive ovarian cancer, in combination with carboplatin. The Company is making Apealea accessible to patients through its partnership with Elevar Therapeutics, together with its existing commercial operations in the Nordic region.

微牛提供Oasmia Pharmaceutical AB(EXMKT-OASMY)的股票价格、实时市场报价、专业分析师评级、深度图表和免费的OASMY股票新闻,以帮助您做出投资决策。

模拟交易:模拟炒股免费实操交易技能。您可用虚拟资金在真实市场环境中零成本、零风险体验交易OASMY股票基本功能。